A plume of smoke signals the final push for the Protos Energy Recovery Facility in Cheshire, where METLEN has successfully ignited its first load of non-recyclable waste. This operational breakthrough marks the transition into hot commissioning for the site, which aims to convert residual household trash into baseload power.
A successful international Phase 3 trial in melanoma has vaulted personalized mRNA cancer therapies into the spotlight, prompting a surge in clinical validation across China. As domestic developers like Beijing-based Likang Life Sciences advance their pipelines, the industry is shifting focus from early research toward high-efficiency, individualized manufacturing.
Spanning 1,700 acres along the Kissimmee River, Westgate River Ranch has been tapped by Consumer365 as the premier 2026 destination for homeschooling families. The resort is gaining traction for its ability to weave academic concepts like biology, regional history, and agricultural science into traditional outdoor vacations.
The artist behind the iconic Sexy Robot series has severed his long-standing management agreement with Nanzuka Gallery to launch Sorayama Hajime Estate Co., Ltd. The newly formed entity now serves as the sole authority for his licensing, brand collaborations, and the management of his global artistic portfolio moving forward.
A 132% surge in sales for its lead drug Kangyueda pushed Keymed Biosciences into profitability during the first half of 2026. The Chengdu-based biotech reported RMB122 million in profit, a sharp reversal from previous losses, bolstered by milestone payments from AstraZeneca and a strengthening global drug pipeline.
Seoul-based skincare brand AXIS-Y is challenging industry standards by launching a recovery serum that replaces traditional salmon-derived PDRN with a plant-based alternative. The Triple PDRN Barrier Boost Serum utilizes DNA-inspired golden peptide threads to deliver concentrated nutrients, marking a shift toward high-performance vegan formulations in the competitive Korean beauty market.
China's National Medical Products Administration has accepted the New Drug Application for Opamtistomig, a bispecific antibody targeting PD-L1 and 4-1BB. Developed by Nanjing Leads Biolabs, the drug is positioned to become the world's first approved therapy of its kind, potentially establishing a new benchmark in immuno-oncology for aggressive tumors.
Investors who held ADMA Biologics shares between August 9, 2024, and March 25, 2026, are being urged to join a class action lawsuit. The litigation targets the company for alleged violations of the Securities Exchange Act, specifically concerning misleading statements regarding its financial health and sales practices.
Investors who purchased ADMA Biologics shares between August 9, 2024, and March 25, 2026, are being urged to join a class action lawsuit filed by Schall, Brown & Schwartz LLP. The litigation centers on claims that the company misled the market through undisclosed transactions and inflated revenue figures.
Investors who purchased Regeneron Pharmaceuticals shares between August 1, 2025, and May 15, 2026, face a critical deadline as a class action lawsuit moves forward. The DJS Law Group is currently organizing shareholders to address allegations that the company misled the public regarding the outcomes of its Phase III Fianlimab-Libtayo study.
Investors who purchased ZoomInfo Technologies stock between November 3, 2025, and May 11, 2026, face an August 24 deadline to join a class action lawsuit. The litigation alleges the company misled shareholders regarding the market trajectory and competitive viability of its AI-powered product suite.
Borussia Dortmund GmbH & Co. KGaA convenes its annual press conference in Germany today at 11:30 CET to present the preliminary financial figures for the 2025/2026 fiscal year. The session serves as the primary disclosure for stakeholders tracking the club's economic trajectory following the latest season.
Investors who purchased ZoomInfo Technologies Inc. stock between November 3, 2025, and May 11, 2026, face an August 24, 2026, deadline to seek lead plaintiff status. The class action lawsuit, filed by Schall, Brown & Schwartz LLP, alleges the company misled the market regarding its actual demand and product performance.
A class action lawsuit filed against Genius Group Limited accuses the company of orchestrating a spoofing scheme to artificially inflate market activity. Investors who purchased GNS shares between April 12, 2022, and May 30, 2025, now face an August 28, 2026, deadline to join the litigation seeking recovery for their losses.
Investors who purchased Genius Group Limited securities between April 12, 2022, and May 30, 2025, face an August 28, 2026, deadline to join a class action lawsuit. The litigation, spearheaded by the firm Schall Brown & Schwartz, targets the company for alleged market manipulation and securities law violations.
Investors who purchased Insulet Corporation securities between February 21, 2025, and May 26, 2026, face an August 31, 2026, deadline to join a class action lawsuit. The litigation, filed by Schall Brown & Schwartz, alleges the medical device company misled shareholders regarding manufacturing safety and product defects.
Investors who purchased Insulet Corporation stock between February 21, 2025, and May 26, 2026, are facing a deadline to join a class action lawsuit. The litigation alleges the company violated federal securities laws by issuing misleading statements regarding its internal manufacturing controls and product safety standards.
Investors who purchased Photronics, Inc. shares between December 10, 2025, and May 27, 2026, are facing a critical deadline to join a class action lawsuit. The DJS Law Group is currently organizing shareholders to address allegations that the company provided false and misleading financial forecasts during this period.
Shareholders who acquired Photronics, Inc. stock between December 10, 2025, and May 27, 2026, face a September 4, 2026, deadline to seek lead plaintiff status in a pending securities fraud lawsuit. The litigation targets alleged misrepresentations regarding the company’s internal growth projections and operational capacity.
Investors who purchased Planet Fitness shares between November 6, 2025, and May 6, 2026, are being urged to join a securities class action lawsuit. The filing alleges the gym operator misled the market regarding the effectiveness of its marketing campaigns and the implementation of its national Black Card price hikes.
Investors who purchased GPGI, Inc. shares between November 3, 2025, and May 6, 2026, face a critical September 15 deadline to join a class action lawsuit. The litigation targets alleged violations of the Securities Exchange Act, centering on claims that the company misled the market regarding its acquisition of Husky Technologies.
Investors who held DNOW Inc. shares as of August 5, 2025, have until October 2, 2026, to seek lead plaintiff status in a class action lawsuit. The litigation targets alleged misrepresentations regarding integration hurdles following the company’s merger with MRC Global Inc. that impacted shareholder value.
Shareholders who purchased GPGI, Inc. stock between November 3, 2025, and May 6, 2026, face a September 15, 2026, deadline to join a class action lawsuit. The litigation, led by Schall Brown & Schwartz LLP, alleges the company misled investors regarding the financial health and value of its Husky Technologies acquisition.
Investors who held DNOW Inc. stock leading up to the company’s September 2025 special meeting are being urged to join a class action lawsuit. The litigation alleges that the energy equipment provider misled shareholders regarding the integration hurdles of its merger with MRC Global Inc.
Investors who purchased Rackspace Technology stock between May 7 and July 8, 2026, are being urged to join a class action lawsuit filed against the cloud computing firm. The litigation claims the company misled shareholders regarding its financial health while aggressively redirecting resources toward artificial intelligence initiatives.
A federal securities class action lawsuit now targets Rackspace Technology, Inc. over allegations of misleading financial disclosures. Shareholders who acquired RXT stock between May 7, 2026, and July 8, 2026, face an upcoming September 28, 2026, deadline to seek appointment as lead plaintiff in the ongoing litigation.
Shareholders who purchased Pentair plc stock between April 28 and July 14, 2026, face an October 2 deadline to join a class action lawsuit. The litigation alleges the company misled the market regarding significant destocking issues within its Pool channel, which negatively impacted financial performance and share value.
Investors who purchased Capricor Therapeutics stock between December 17, 2025, and July 26, 2026, are being urged to join a class action lawsuit. The firm Schall, Brown & Schwartz LLP claims the company misled shareholders regarding the statistical analysis of its lead drug candidate, Deramiocel, ahead of an FDA review.
Geopolitical shifts and central bank decisions rarely align with the traditional Monday-to-Friday trading schedule, prompting STARTRADER to debut XAUUSD247. The new CFD instrument offers investors continuous gold quotes throughout the weekend, bridging the gap between standard market sessions and the volatile events that frequently occur while global exchanges remain closed.
Investors who purchased Wix.com stock between February 19, 2025, and May 12, 2026, face an upcoming September 22 deadline to join a class action lawsuit. The litigation alleges the company misled shareholders regarding the actual development costs and competitive standing of its proprietary artificial intelligence tools.
